Mesoblast & Cartherics to develop off the shelf cancer treatment

Company News

by Anna Napoli

Cellular medicine company, Mesoblast (ASX:MSB) has partnered with Cartherics to develop an off the shelf treatment for solid cancer.

The company says off the shelf CAR-T therapies have the potential to dramatically reduce treatment costs.

The partnership could open up the very effective treatment to millions of cancer patients across the world.

Initial targets are relapsed ovarian and gastric cancers.

The program will be funded by $12.6 million from collorators in the Australian Governments Cooperative Research Program.

Shares in Mesoblast (ASX:MSB) are trading 3.41 per cent higher to $1.52.

Anna Napoli

Finance News Network
Anna joined FNN February 2018 and also works with Channel 7 as a freelance producer. Anna has also worked as a lawyer and lecturer. She has also presented news updates for interstate news with Southern Cross Austereo.